证券代码：300363 证券简称：博腾股份 编号：00620200529 | --- | --- | --- | |------------------------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | ■特定对象调研 □分析师会议 | | 投资者关系活 | □媒体采访 | □业绩说明会 | | 动类别 | | □新闻发布会 □路演活动 | | | □现场参观 | □电话通讯 | | | □其他 | | | | | 国盛证券：张金洋、胡偌碧；中金基金：兰兰；国金资管： | | | | 朱明睿；大成基金：向秋静；星石投资：王雪刚；博时基金： 孔令熙；华商基金：孙蔚；中庚基金：郑宁；混沌投资：张 | | 参与单位名称 及人员姓名 | | 肖星、张昕 ...

证券代码：300363 证券简称：博腾股份 博腾股份投资者关系活动记录表 编号：00920191205 | --- | --- | --- | |-------------------------|------------------------------------|----------------------------------------------------------| | | | | | | ■特定对象调研 □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | □电话通讯 | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | | 弘则弥道（上海）投资咨询有限公司：郭望葳 | | 时间 | 2019 年 12 月 05 日 | | | 地点 | 公司 2-1 会议室 | | | 上市公司接待人 员姓名 | 证券事务代表皮薇，董事会办公室陈靓 | | | | | | | | 公司与投资者交流情况如下： | | | | Q1 ：公司战略发展差异化在哪里？ | | ...

证券代码：300363 证券简称：博腾股份 编号：00820191128 | --- | --- | --- | |-----------------------------|-------------------------------------|--------------------------------------------------------| | | | | | | ■特定对象调研 □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | □电话通讯 | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 人员姓名 | 国盛证券：张金洋 中信建投证券：俞冰 | 中银基金：陈军、刘潇、刘浩宇、陈哲、王方舟、杨雷 | | 时间 | 2019 年 11 月 28 日 | | | 地点 公司 | 2-1 会议室 | | | 上市公司接待人 员姓名 | | 副总经理吉耀辉，证券事务代表皮薇，董事会办公室陈靓 | | | 公司与投资者交流情况如下： | | | | Q1 | ：请介绍一下 ...

证券代码：300363 证券简称：博腾股份 博腾股份投资者关系活动记录表 编号：00720191112 | --- | --- | --- | |-------------------------|--------------------------------------|----------------------------------------------------| | | | | | | ■特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | | □现场参观 | □电话通讯 | | | □其他 （请文字说明其他活动内容） | | | 参与单位名称及 人员姓名 | 北京源乐晟资产管理有限公司：欧阳明 | | | 时间 | 2019 年 11 月 12 日 | | | 地点 公司 | 2 楼视频会议室 | | | 上市公司接待人 员姓名 | 证券事务代表皮薇、董事会办公室汪星星 | | | | 公司与投资者交流情况如下： | | | | Q1 ： 2019 年前三季度，公司 | CRO 业务中 J-STAR ...

证券代码：300363 证券简称：博腾股份 | --- | --- | --- | --- | |-------------------------|----------------------------------|--------------------------------------------------------|--------------------------------| | | | 编号：00320190821 | | | | █特定对象调研 □分析师会议 | | | | | □媒体采访 | □业绩说明会 | | | 投资者关系活 | □新闻发布会 □路演活动 | | | | 动类别 | □现场参观 | □电话通讯 | | | | □其他 | （请文字说明其他活动内容） | | | 参与单位名称 及人员姓名 | 信达证券 周贤珮 | | | | 时间 2019 | 年 08 月 21 日 | | | | 地点 水土 | 2-1 会议室 | | | | 上市公司接待 | 皮薇 证券事务代表 | | | | 人员姓名 | 陈靓 投资者关系主管 | | | | | 一、证券事务代表介绍公 ...

Group 1: Business Transformation and Growth - The company has over 400 active projects across various stages from clinical to market, and a client base of over 300, which are crucial for future growth [3] - The CRO and API businesses are on a growth trajectory, with short-term growth reflected in project numbers and long-term growth expected from increased business flow and client retention [3] - The management is focused on enhancing organizational capabilities and core competitiveness within the CDMO sector, anticipating stable future business development [3] Group 2: Human Resources and Efficiency - The company has approximately 1,800 employees, which is half the number compared to peers, leading to higher per capita revenue output due to different asset structures and business attributes [3] - Despite a modest increase in total personnel, the number of R&D staff has doubled, and there has been significant growth in sales and marketing personnel [3] - The company delivered 44 API projects in 2018 and 34 in the first half of 2019, indicating a strong operational capacity in the CMO business [3][4] Group 3: Product Pipeline and Market Strategy - The largest single product in the pipeline generates annual revenue of around 100 million RMB, with products achieving over 5 million USD in annual sales considered high-value [4] - The company is cautious about high client and product concentration risks, ensuring a diverse product pipeline to support stable development [4] - The company maintains an open yet cautious approach towards acquisitions, focusing on internal development and potential small-scale acquisitions for unique technological capabilities [4]

Group 1: Company Overview - As of Q3 2019, the total number of employees at Boteng Co. reached 1,999, with 364 in R&D, serving over 300 clients [3] - The company operates two main production bases located in Chongqing and Yichun, with a total capacity of approximately 1,191 cubic meters [3] - The Chongqing facility has 10 workshops with a capacity of nearly 700 cubic meters, while the Yichun facility has 6 workshops with a capacity of about 491 cubic meters [3] Group 2: Financial Performance - In the first three quarters of 2019, Boteng Co. achieved a revenue of 1.08 billion yuan, representing a year-on-year growth of approximately 30% [4] - The net profit for the same period was 140 million yuan, with a year-on-year increase of 39% [4] - The gross profit margin improved to 37.5%, an increase of about 3.6 percentage points compared to the previous year [4] Group 3: Business Segments - The CRO business generated revenue of 305 million yuan in the first three quarters, with 138 products contributing to the income [3] - The European market accounted for 39% of sales, while North America represented 26%, marking significant growth in these regions [3] - The product pipeline included 238 products sold, with 108 being new products and 138 being existing products [3] Group 4: R&D and Capacity Expansion - The company plans to increase R&D personnel by 100 each year over the next two years [4] - In 2019, investments in crystallization and enzyme catalysis technologies amounted to approximately 10 million yuan and 20 million yuan, respectively [5] - The company aims to enhance production efficiency, with a 60% increase in production batches per week compared to the previous year [4] Group 5: Strategic Direction - Boteng Co. is focusing on a CDMO model that emphasizes "traffic × conversion × monetization," integrating CRO and CMO services to enhance monetization capabilities [5] - The company recognizes the importance of understanding industry cycles, particularly in oncology and rare diseases, to identify growth opportunities [6] - The acquisition of J-STAR has expanded its team from 40 to 98 members, enhancing its capabilities in the U.S. market [6]

Group 1: Company Overview and Strategy - Chongqing Boteng Pharmaceutical Technology Co., Ltd. was established in 2005, initially focusing on serving large clients like Johnson & Johnson in the CMO industry [1] - The company adopted a "big client" strategy to optimize resource allocation and gradually expanded its client base and product lines [1] - In 2014, the business development strategy was adjusted to include both large and small clients, which remains a key focus for the company [1] Group 2: Shareholding Structure - The actual controllers of the company are three individuals, collectively holding approximately 44% of the shares [1] - A transaction is in progress for QING SHAO to acquire 6.47% of the shares, which will make the fund under China Merchants Capital a strategic shareholder with over 5% ownership [2] Group 3: Financial Management and Risk - The company is aware of the high pledge ratio of major shareholders and is taking measures to manage associated risks [2] - A price adjustment mechanism is in place with overseas clients to mitigate the impact of significant exchange rate fluctuations [2] - The company is cautious about using foreign exchange hedging tools due to past losses experienced by other firms [2] Group 4: Production Capacity and Financial Performance - The overall capacity utilization rate for the company's three bases was not very high last year, with Long寿 and Jiangxi Dongbang bases at approximately 60% and Zhejiang Shangyu base at about 40% [2] - The company reported strong operating cash flow, marking the best performance in the past three years, with high-quality accounts receivable from multinational pharmaceutical clients [3] - Capital expenditures will be reduced this year, focusing only on fundraising projects without significant additional investments [3]

Group 1: 2017 Performance Overview - The company's 2017 revenue is expected to decline by 0%-10%, while net profit attributable to shareholders is projected to decrease by 30%-40% due to significant fluctuations from two major clients [1] - Despite the revenue decline, sales growth from other clients helped maintain overall revenue stability in 2017 [1] - The profit decline is attributed to increased financial expenses, operating costs, and fixed asset depreciation [1] Group 2: 2018 Business Focus - In 2018, the company will focus on three key business areas: API projects, the Chinese market, and CRO services [2] - The company secured approximately 20 million in orders from Chinese clients in 2017 and anticipates further growth in this area due to increased domestic client visits [2] - Following the acquisition of J-STAR Research in 2017, the company plans to strengthen its CRO business and establish a J-STAR China division in Shanghai [2] Group 3: Future Plans and Strategies - The company is currently evaluating potential investors for its private placement, which is based on market price inquiries [3] - The CMO project for biopharmaceuticals is expected to launch in the first half of 2018, with a construction period of three years [3] - The introduction of China Merchants Capital as a strategic investor aims to stabilize shareholder reductions and improve the company's equity and governance structure [3] Group 4: Business Model and Strategy - The company aims to develop a "pharmaceutical service platform" strategy, focusing on both chemical and biological drugs [3] - Future plans include extending services from CMO to CRO, creating a comprehensive end-to-end service system [3]

Group 1: Revenue and Client Concentration - In 2016, the revenue from the top two clients, including Johnson & Johnson, accounted for approximately 70% of total revenue. It is expected to decrease to around 50% in 2017, with a goal to limit single client revenue concentration to no more than 25% in the future [1] Group 2: CRO Business Development - The company has a dedicated CRO team, primarily based in the US and Shanghai, with an addition of approximately 100 R&D personnel last year. The company plans to continue expanding its R&D team to enhance CRO capabilities [1] Group 3: Market Expansion and Performance - The company is pursuing an end-to-end model in the pharmaceutical service platform, with significant growth in the domestic market observed in the first two months of the current year, indicating a potential breakthrough year [2] Group 4: Financial Management and Risks - The company is focused on reducing the high pledge ratio of shares held by the three actual controllers, as part of their core work this year, following previous investments funded through share pledges [2] - The majority of the company's settlements are in USD, and there have been exchange losses due to currency fluctuations. The company is researching hedging measures to mitigate exchange rate risks [2] Group 5: Product Pipeline - The company has a pipeline of hundreds of projects, including commercialized products and those in clinical stages, with a focus on diabetes combined with heart failure drugs, anti-tumor drugs, and BTK inhibitors [3]